Zynerba Pharmaceuticals Announces Acceptance of Poster at

DEVON, Pa., May 27, 2021 (GLOBE NEWSWIRE) – Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative transdermal pharmaceutical cannabinoid therapies for rare and near rare neuropsychiatric disorders, today announced the acceptance and details of poster presentation at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. ASCP’s annual meeting will be held virtually June 1-4, 2021. A copy of the poster will be available on the Zynerba Company website at the time of the presentation at http://zynerba.com / publications /.

Title ZYN002 transdermal cannabidiol gel: efficacy and safety results in children and adolescents
With autism spectrum disorder (ASD) and related disorders
Session Poster Session II
Dated June 3, 2021
Time 10:00 am – 11:00 am ET

About Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals is the leader in innovative transdermal cannabinoid pharmaceutical therapies for rare and near rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with serious chronic health conditions, including Fragile X Syndrome, Autism Spectrum Disorders, 22q11.2 Deletion Syndrome and a heterogeneous group of rare and ultra-rare epilepsies known as developmental epilepsy and epilepsy. encephalopathies. Learn more at www.zynerba.com and follow us on Twitter at @ZynerbaPharma.

Caution regarding forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We may, in certain circumstances, use terms such as “predict”, “believe”, “potential”, “proposed”, “continue” , “” estimates “,” anticipates “,” expects “,” plans “,” intends “,” may “,” could “,” could “,” will “,” should “or d ” other words which reflect the uncertainty of future events or results to identify these forward-looking statements. These statements are subject to many important factors, risks and uncertainties which may cause actual events or results to differ materially from current expectations The expectations of management and, accordingly, the forward-looking statements contained in this press release may also be affected by risks and uncertainties relating to a number of other factors, including the following: the Company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as expected; the Company’s expectations, projections and estimates regarding expenses, future income, capital requirements, eligibility for incentives and other tax credits, collectability and timing, and availability and need for financing additional; the Company’s ability to obtain additional financing to support its clinical development programs; the results, costs and timing of the Company’s clinical development programs, including any delay in such clinical trials related to recruitment or site initiation; the clinical results of the Company’s product candidates may not be replicated or continue to occur in additional trials and may otherwise not support further development in a specified indication or not at all; actions or advice of the United States Food and Drug Administration and foreign regulatory agencies may affect the design, initiation, timing, continuation and / or progress of clinical trials or result in the need for clinical trials additional; the Company’s ability to obtain and maintain regulatory approval for its product candidates, and labeling under such approval; the Company’s dependence on third parties to assist it in conducting preclinical and clinical trials for its product candidates; delays, interruptions or failures in the manufacture and supply of the Company’s product candidates; the Company’s ability to market its product candidates; the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to serve these markets; the Company’s ability to develop its commercial and marketing capacities, alone or with potential future employees; the rate and degree of market acceptance of the Company’s product candidates; the Company’s expectations regarding its ability to obtain and adequately maintain sufficient intellectual property protection for its product candidates; the timing and outcome of current and future legal proceedings; and the extent to which health and other communicable disease outbreaks, including COVID-19, could disrupt our operations or negatively affect our business and financial conditions. This list is not exhaustive and these and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed or provided to the Securities and Exchange Commission and available at www.sec.gov. All forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

Investor contact

Pierre Vozzo
Westwicke / ICR
Office: 443.213.0505
Cell: 443.377.4767
[email protected]

About Keith Tatum

Check Also

PQ Group Holdings Announces Successful Pricing and Granting of Senior Secured Term Loan Facility

MALVERN, Pa .– (COMMERCIAL THREAD) – PQ Group Holdings Inc. (NYSE: PQG), a leading global …